HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men
- Registration Number
- NCT06498505
- Lead Sponsor
- University of Zurich
- Brief Summary
Randomized clinical trial evaluating the effect of acetazolamide on pulmonary artery pressure in women compared to men travelling to 3600 m.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 270
- Healthy, non-smoking men and women, age 18-44 years, without any diseases and need of regular medication (including oral contraceptives).
- BMI >18 kg/m2 and <30 kg/m2
- Born, raised and currently living at altitudes <1000 m
- Written informed consent
- Premenopausal women with an eumenorrheic cycle
- Other types of contraceptvies (hormonal intrauterine device, vaginal ring, subcutaneous injections or implants, among others)
- Pregnancy or nursing
- Anaemic (haemoglobin concentration <10g/dl)
- Any altitude trip <4 weks before the study
- Allergy to acetazolamide and other sulfonamides
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description WOMEN - PLACEBO oral capsule Placebo Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m. MEN - PLACEBO oral capsule Placebo Placebo (capsules identically looking as acetazolamide capsules; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m. MEN - ACETAZOLAMIDE oral capsule Acetazolamide Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m WOMEN - ACETAZOLAMIDE oral capsule Acetazolamide Acetazolamide 250 mg/day (capsules @125 mg; 1 in the morning, 1 in the evening), orally. Medication starts 24 hours before ascent to 3600 m until the morning after the second night at 3600 m
- Primary Outcome Measures
Name Time Method Pulmonary artery Pressure (PAP) Day 2 at 760 m and Day 2 at 3600 m Sex-related difference in the altitude-induced change in RV/RA in mmHg assessed by echocardiography between acetazolamide and placebo group.
- Secondary Outcome Measures
Name Time Method Lung comets Day 2 at 760 m and Day 2 at 3600 m Sex-related difference in the altitude-induced change in ultrasound lung comets assessed by echocardiography between acetazolamide and placebo group.
Parameters of right heart function Day 2 at 760 m and Day 2 at 3600 m Sex-related difference in the altitude-induced change in parameters of right heart function assessed by echocardiography between acetazolamide and placebo group.
Trial Locations
- Locations (1)
National Center for Cardiology and Internal Medicine
🇰🇬Bishkek, Kyrgyzstan